Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report sent to investors on Sunday morning. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Performance

BTX stock opened at $1.80 on Friday. Brooklyn ImmunoTherapeutics has a fifty-two week low of $0.17 and a fifty-two week high of $10.10. The business’s 50 day moving average price is $1.79 and its two-hundred day moving average price is $1.98. The company has a market capitalization of $105.89 million, a price-to-earnings ratio of -0.77 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.